The content on this site is intended for healthcare professionals only
Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...
Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...
6 Jun 2022
ASCO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
6 Jun 2022
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
Dr Etienne Brain - Institut Curie, Paris, France
6 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
5 Jun 2022
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...
Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA
5 Jun 2022
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...
Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA
5 Jun 2022
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...
Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA
5 Jun 2022
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone rece...
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
4 Jun 2022
Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer
Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA
4 Jun 2022
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
4 Jun 2022
Cancer Services Delivery: Focus on India
Dr Soumitra Datta - Tata Medical Center, Kolkata, India
26 May 2022
Diagnostic performance and survival outcome of SLNB procedure in breast cancer p...
Dr Sanjit Kumar Agrawal - Tata Medical Center, Kolkata, India
25 May 2022